UroAlerts - Prostate Cancer Weekly

Neal Shore describes the MEVPRO-2 trial design, a 900-patient double-blind randomized study of mevrometostat 875 mg twice daily with food plus enzalutamide versus enzalutamide alone in ARPI-naive mCRPC patients.

Elisabeth Heath discusses the FDA approval of capivasertib for PTEN-deficient metastatic hormone-sensitive prostate cancer, reviewing CAPItello-281 data in de novo patients randomized to capivasertib plus abiraterone versus abiraterone alone, both with ADT.